We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
-0.77%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.55B
AUM Growth
-$472M
(-5.9%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-3.99%
Top 10 Holdings %
Top 10 Hldgs %
20.77%
Holding
863
New
59
Increased
344
Reduced
256
Closed
128
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nike
NKE
|
+$25.4M |
| 2 |
AbbVie
ABBV
|
+$21.9M |
| 3 |
KYNB
Kyntra Bio
KYNB
|
+$19.2M |
| 4 |
Waste Management
WM
|
+$19M |
| 5 |
Gilead Sciences
GILD
|
+$17.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$70.2M |
| 2 |
ARRY
Array Biopharma Inc
ARRY
|
+$45.8M |
| 3 |
Biogen
BIIB
|
+$43.3M |
| 4 |
Meta Platforms (Facebook)
META
|
+$24.8M |
| 5 |
Amgen
AMGN
|
+$21.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 31.81% |
| 2 | Technology | 18.27% |
| 3 | Financials | 10.05% |
| 4 | Consumer Discretionary | 9.39% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Assurant
AIZ
$13.7B
| $1.46M | 0.02% |
11,589
+1,018
| +10% | +$121K |
|
527
Itaú Unibanco
ITUB
$92.3B
| $1.44M | 0.02% |
234,613
+7,031
| +3% | +$45.6K |
|
528
Wabtec
WAB
$50.8B
| $1.42M | 0.02% |
19,793
+1,683
| +9% | +$120K |
|
529
Align Technology
ALGN
$12B
| $1.38M | 0.02% |
7,643
+2,414
| +46% | +$502K |
|
530
Cincinnati Financial
CINF
$28.5B
| $1.38M | 0.02% |
11,793
+77
| +0.7% | +$8.47K |
|
531
Bank of Montreal
BMO
$125B
| $1.37M | 0.02% |
18,539
-872
| -4% | -$63.5K |
|
532
Expeditors International
EXPD
$22.4B
| $1.34M | 0.02% |
18,064
+4,079
| +29% | +$299K |
|
533
Conagra Brands
CAG
$7.29B
| $1.33M | 0.02% |
43,506
+3,884
| +10% | +$112K |
|
534
CoStar Group
CSGP
$11.9B
| $1.33M | 0.02% |
+22,490
| New | +$1.35M |
|
|
PPLI
535
People Inc
PPLI
$3.15B
| $1.33M | 0.02% |
34,188
+1,354
| +4% | +$57.8K |
|
536
Alexandria Real Estate Equities
ARE
$8.96B
| $1.31M | 0.02% |
8,528
+8,520
| +106,500% | +$1.26M |
|
537
Markel Group
MKL
$25.2B
| $1.31M | 0.02% |
1,112
+154
| +16% | +$175K |
|
538
Kimco Realty
KIM
$17.8B
| $1.3M | 0.02% |
62,338
-291
| -0.5% | -$5.54K |
|
539
Arch Capital
ACGL
$36.3B
| $1.29M | 0.02% |
30,768
+190
| +0.6% | +$7.49K |
|
540
AngioDynamics
ANGO
$565M
| $1.29M | 0.02% |
70,000
| – | – |
|
541
Iovance Biotherapeutics
IOVA
$2.19B
| $1.26M | 0.02% |
69,500
+21,500
| +45% | +$475K |
|
542
Mid-America Apartment Communities
MAA
$15.5B
| $1.26M | 0.02% |
+9,727
| New | +$1.21M |
|
543
BioLife Solutions
BLFS
$1.46B
| $1.26M | 0.02% |
76,000
| – | – |
|
544
International Flavors & Fragrances
IFF
$19.5B
| $1.25M | 0.02% |
10,181
+1,952
| +24% | +$249K |
|
545
W.P. Carey
WPC
$17B
| $1.24M | 0.02% |
+14,186
| New | +$1.21M |
|
546
C.H. Robinson
CHRW
$20.6B
| $1.24M | 0.02% |
14,652
-71,373
| -83% | -$6M |
|
547
Lennar Class A
LEN
$20.5B
| $1.24M | 0.02% |
22,952
+2,208
| +11% | +$108K |
|
|
TPTX
548
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $1.24M | 0.02% |
+33,000
| New | +$1.44M |
|
549
ResMed
RMD
$29.5B
| $1.23M | 0.02% |
9,100
-401
| -4% | -$52.5K |
|
|
FLIR
550
DELISTED
FLIR Systems, Inc. (DE) Common Stock
FLIR
| $1.23M | 0.02% |
23,338
-52,895
| -69% | -$2.7M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2019 Portfolio in Review
As of Q3 2019, Candriam SCA held 863 positions worth $7.55B, down 5.9% from $8.02B the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Candriam SCA withdrew a net $301M in Q3 2019, closing 128 positions and reducing 256 holdings. Its most notable exit was Celgene Corp, an estimated $70.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 32% of assets, down from 33% a quarter earlier, followed by Technology and Financials.
Against the trend, Candriam SCA opened a new position in Nike worth $27.8M.
- Candriam SCA's largest Q3 2019 buy was Nike: 295,763 shares worth $27.8M.
- Candriam SCA added most to AbbVie in Q3 2019, an estimated $21.9M increase.
- Candriam SCA's biggest Q3 2019 reduction was Biogen, cutting an estimated $43.3M.
- Candriam SCA fully exited Celgene Corp in Q3 2019, selling an estimated $70.2M.
- Candriam SCA's ten largest holdings make up 21% of its $7.55B portfolio in Q3 2019.
- Candriam SCA opened 59 new positions and closed 128 in Q3 2019.
- Candriam SCA's portfolio value fell 5.9% quarter-over-quarter to $7.55B.
Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.